Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
On March 12, 2020, Idera Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2019. As set forth below, the Company is furnishing the press release as Exhibit 99.1 to this Current Report on Form 8-K.
(a) Financial Statements of Businesses Acquired.
None.
(b) Pro Forma Financial Information.
None.
(c) Shell Company Transactions.
None.
(d) Exhibits.
| 99.1 | Press Release by the Company, dated March 12, 2020, furnished in accordance with Item 2.02 of this Current Report on Form 8-K. |
IDERA PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 tm2012492d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Idera Pharmaceuticals Contacts: Jill Conwell John J. Kirby Investor Relations & Chief Financial Officer Corporate Communications Phone (484) 348-1627 Phone (484) 348-1675 [email protected] [email protected] Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update – Completed Enrollment in ILLUMINATE-301; Top-Line Overall Response Rate (ORR) Data Expected in Q1 2021 – EXTON,…
To view the full exhibit click here
About Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400; IMO-2125/IMO-2055, and IMO-9200. The Company’s TLR antagonist lead drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. Its TLR agonist lead drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9.
